Personalized treatment for DLBCL guided by ctDNA
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a way to use your tumor's DNA (called ctDNA) to choose a targeted treatment for your newly diagnosed DLBCL. It aims to see if this personalized approach works better than standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have not yet started treatment for your lymphoma.
- Your lymphoma has a protein called CD20 on its surface (CD20-positive).
- Your overall health is good (ECOG score of 0, 1, or 2).
- Your IPI risk score is 2, 3, 4, or 5 (meaning moderate to high risk).
- You are between 18 and 75 years old.
- You do not have a known allergy to the drugs in this trial (like R-CHOP, obinutinib, etc.).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called birelentinib combined with standard chemotherapy (R-CHOP) for people who have just been diagnosed with a type of lymphoma called DLBCL. The goal is to see if the combination works better than R-CHOP alone.
This trial studies whether using a blood test (ctDNA) can help guide treatment decisions for people with newly diagnosed diffuse large B-cell lymphoma. It tests standard chemotherapy regimens (R-CHOP or R-pola-CHP) and aims to improve outcomes by monitoring tumor DNA in the blood.
This study looks at whether blood tests for tumor DNA (cfDNA) can help guide treatment decisions for people with newly diagnosed DLBCL. It focuses on patients who achieve complete remission after 6 rounds of R-CHOP chemotherapy.
This trial tests if a new drug combination works better than the standard treatment for people with a specific, aggressive form of diffuse large B-cell lymphoma (DLBCL) that shows high levels of two proteins, MYC and BCL2. The study aims to improve outcomes by using genetic information to guide treatment choices.
This trial uses a blood test (ctDNA) and PET scans to predict how well standard first-line treatment works for diffuse large B-cell lymphoma (DLBCL). It aims to find out if these tests can guide better care.
This trial tests whether adding a drug called decitabine to the standard chemo-immunotherapy R-CHOP can help people with a specific type of lymphoma (DLBCL that is positive for EBV) who have not been treated before. The goal is to see if the combination works better than R-CHOP alone.
Hear when a new Diffuse Large B Cell Lymphoma (DLBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.